--- title: "Xintian Pharma: Xinlikang capsules approved to conduct clinical trials for the treatment of cancer-related fatigue" type: "News" locale: "en" url: "https://longbridge.com/en/news/261012598.md" description: "According to the Zhitong Finance APP, Xintian Pharma announced that the company recently received the \"Drug Clinical Trial Approval Notice\" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for \"treatment of cancer-related fatigue.\"" datetime: "2025-10-14T08:37:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/261012598.md) - [en](https://longbridge.com/en/news/261012598.md) - [zh-HK](https://longbridge.com/zh-HK/news/261012598.md) --- # Xintian Pharma: Xinlikang capsules approved to conduct clinical trials for the treatment of cancer-related fatigue According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for "the treatment of cancer-related fatigue." ### Related Stocks - [002873.CN](https://longbridge.com/en/quote/002873.CN.md) ## Related News & Research - [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md) - [METiS TechBio presents late-breaking cardiomyocyte LNP delivery data at CRS meeting](https://longbridge.com/en/news/287051904.md) - [Orkla’s OV UK Buys Phoenix Brands to Boost Sweet Ingredients Footprint](https://longbridge.com/en/news/286763926.md) - [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md) - [](https://longbridge.com/en/news/286948461.md)